Blueprint Medicines Corp (BPMC)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] by (Cboe BZX)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] [[ item.lastPriceExt ]] [[ item.priceChangeExt ]] ([[ item.percentChangeExt ]]) [[ item.tradeTimeExt ]]
for [[ item.sessionDateDisplayLong ]]
Fiscal Year End Date: 12/31
(Values in U.S. thousands)
12-2023 | 12-2022 | 12-2021 | 12-2020 | 12-2019 | |
Sales | 249,380 | 204,036 | 180,080 | 793,735 | 66,512 |
Cost of Goods | 12,796 | 26,761 | 25,735 | 425 | N/A |
Gross Profit | 236,584 | 177,275 | 154,345 | 793,310 | 66,512 |
Operating Expenses | 723,657 | 715,554 | 797,061 | 485,028 | 427,838 |
Operating Income | -486,277 | -537,518 | -641,981 | 308,707 | -361,326 |
Other Income | -19,739 | -14,763 | 897 | 6,233 | 13,632 |
Pre-tax Income | -506,016 | -552,281 | -641,084 | 314,940 | -347,694 |
Income Tax | 968 | 5,236 | 3,001 | 1,058 | N/A |
Net Income Continuous | -506,984 | -557,517 | -644,085 | 313,882 | -347,694 |
Net Income | $-506,984 | $-557,517 | $-644,085 | $313,882 | $-347,694 |
EPS Basic Total Ops | -8.37 | -9.35 | -11.01 | 5.76 | -7.27 |
EPS Basic Continuous Ops | -8.37 | -9.35 | -11.01 | 5.76 | -7.27 |
EPS Diluted Total Ops | -8.37 | -9.35 | -11.01 | 5.59 | -7.27 |
EPS Diluted Continuous Ops | -8.37 | -9.35 | -11.01 | 5.59 | -7.27 |
EPS Diluted Before Non-Recurring Items | -8.37 | -9.35 | -6.60 | 5.59 | -7.27 |
EBITDA(a) | $-492,078 | $-526,765 | $-634,141 | $315,732 | $-361,016 |